IMMUNITYBIO, INC. (IBRX) Operating income 2016–2025
IMMUNITYBIO, INC. (IBRX) annual operating income history from SEC filings — each fiscal year as reported.
-$256.0MFY2025 · since FY2016: -$124.5M → -$256.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$256.0M | +25.6% |
| FY2024 | -$344.2M | +5.0% |
| FY2023 | -$362.3M | -3.1% |
| FY2022 | -$351.3M | -6.4% |
| FY2021 | -$330.3M | -49.5% |
| FY2020 | -$220.9M | -41.4% |
| FY2019 | -$156.3M | -58.8% |
| FY2018 | -$98.4M | +0.7% |
| FY2017 | -$99.1M | +20.4% |
| FY2016 | -$124.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Gross marginIBRX Operating marginIBRX Operating cash flowIBRX Free cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →